The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
Open accessAbstract
Advances in cancer immunity have promoted a major breakthrough in the field of cancer therapy. This is mainly associated with the successful development of immune checkpoint inhibitors (ICIs) for multiple types of human tumors. Blockade with different ICIs, including programmed cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, may activate the immune system of the host against malignant cells. However, only a subgroup of patients with cancer would benefit from immune checkpoint blockade. Some patients experience primary resistance to initial immunotherapy, and a majority eventually develop acquired resistance to ICIs. However, the mechanisms involved in the development of drug resistance to immune checkpoint blockade remain unclear. Recent studies supported that combination of ICIs and anti-angiogenic agents could be a promising therapeutic strategy for overcoming the low efficacy of ICIs. Moreover, through their direct anti-cancer effect by inhibiting tumor growth and metastasis, anti-angiogenic drugs reprogram the tumor milieu from an immunosuppressive to an immune permissive microenvironment. Activated immunity by immune checkpoint blockade also facilitates anti-angiogenesis by downregulating the expression of vascular endothelial growth factor and alleviating hypoxia condition. Many clinical trials showed an improved anti-cancer efficacy and prolonged survival following the addition of anti-angiogenic agents to ICIs. This review summarizes the current understanding and clinical development of combination therapy with immune checkpoint blockade and anti-angiogenic strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Mok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,303
Self-citationSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,471
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
Aggarwal, V., Tuli, H., Varol, A., Thakral, F., Yerer, M., Sak, K., Varol, M., Jain, A., Khan, M., & Sethi, G. (2019) · Biomolecules · doi:10.3390/biom9110735 · Cited by 1,221
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
Finn, R. S., Ikeda, M., Zhu, A. X., Sung, M. W., Baron, A. D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00808 · Cited by 1,167
Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166
Immune cell promotion of metastasis
Kitamura, T., Qian, B.-Z., & Pollard, J. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3789 · Cited by 1,158
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023
The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis
McAllister, S. S., & Weinberg, R. A. (2014) · Nature Cell Biology · doi:10.1038/ncb3015 · Cited by 966
Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 946
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Anagnostou, V., Smith, K. N., Forde, P. M., Niknafs, N., Bhattacharya, R., White, J., Zhang, T., Adleff, V., Phallen, J., Wali, N., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0828 · Cited by 896
Fukuoka, S., Hara, H., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03296 · Cited by 890
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., et al. (2017) · Nature · doi:10.1038/nature21724 · Cited by 841
Wallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713
Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
Targeting VEGF/VEGFR to modulate antitumor immunity
Yang, J., Yan, J., & Liu, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00978 · Cited by 646
Cunningham, D., Lang, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D. B., Jonker, D., Osborne, S., Andre, N., Waterkamp, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70154-2 · Cited by 643
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608
Bevacizumab plus ipilimumab in patients with metastatic melanoma
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593
Rini, B. I., Cohen, D. P., Lu, D. R., Chen, I., Hariharan, S., Gore, M. E., Figlin, R. A., Baum, M. S., & Motzer, R. J. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr128 · Cited by 579
Improving immune–vascular crosstalk for cancer immunotherapy
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer
Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., DiSimone, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02627 · Cited by 522
VEGF-A splicing: the key to anti-angiogenic therapeutics?
Harper, S. J., & Bates, D. O. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2505 · Cited by 514
Combining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
Hammers, H. J., Plimack, E. R., Infante, J. R., Rini, B. I., McDermott, D. F., Lewis, L. D., Voss, M. H., Sharma, P., Pal, S. K., Razak, A. R. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1985 · Cited by 505
Carretero, R., Sektioglu, I. M., Garbi, N., Salgado, O. C., Beckhove, P., & Hämmerling, G. J. (2015) · Nature Immunology · doi:10.1038/ni.3159 · Cited by 501
Xu, J., Zhang, Y., Jia, R., Yue, C., Chang, L., Liu, R., Zhang, G., Zhao, C., Zhang, Y., Chen, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2484 · Cited by 498
Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30020-8 · Cited by 476
Taylor, M. H., Lee, C.-H., Makker, V., Rasco, D., Dutcus, C. E., Wu, J., Stepan, D. E., Shumaker, R. C., & Motzer, R. J. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01598 · Cited by 435
Hutson, T. E., Lesovoy, V., Al-Shukri, S., Stus, V. P., Lipatov, O. N., Bair, A. H., Rosbrook, B., Chen, C., Kim, S., & Vogelzang, N. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70465-0 · Cited by 404
Immunosuppressive cells in tumor immune escape and metastasis
Liu, Y., & Cao, X. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1376-x · Cited by 400
Liu, C., Peng, W., Xu, C., Lou, Y., Zhang, M., Wargo, J. A., Chen, J. Q., Li, H. S., Watowich, S. S., Yang, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1626 · Cited by 381
Zhou, C., Wu, Y.-L., Chen, G., Liu, X., Zhu, Y., Lu, S., Feng, J., He, J., Han, B., Wang, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4424 · Cited by 372
Self-citationPatel, J. D., Socinski, M. A., Garon, E. B., Reynolds, C. H., Spigel, D. R., Olsen, M. R., Hermann, R. C., Jotte, R. M., Beck, T., Richards, D. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.9626 · Cited by 370
Atkins, M. B., Plimack, E. R., Puzanov, I., Fishman, M. N., McDermott, D. F., Cho, D. C., Vaishampayan, U., George, S., Olencki, T. E., Tarazi, J. C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30081-0 · Cited by 370
Ramalingam, S. S., Dahlberg, S. E., Langer, C. J., Gray, R., Belani, C. P., Brahmer, J. R., Sandler, A. B., Schiller, J. H., & Johnson, D. H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1144 · Cited by 348
Kimura, T., Kato, Y., Ozawa, Y., Kodama, K., Ito, J., Ichikawa, K., Yamada, K., Hori, Y., Tabata, K., Takase, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13806 · Cited by 336
Soria, J.-C., Mauguen, A., Reck, M., Sandler, A. B., Saijo, N., Johnson, D. H., Burcoveanu, D., Fukuoka, M., Besse, B., & Pignon, J.-P. (2013) · Annals of Oncology · doi:10.1093/annonc/mds590 · Cited by 314
Kamoun, W. S., Ley, C. D., Farrar, C. T., Duyverman, A. M., Lahdenranta, J., Lacorre, D. A., Batchelor, T. T., di Tomaso, E., Duda, D. G., Munn, L. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9356 · Cited by 309 · cited 1×
“Nevertheless, anti-VEGF agents are reported to decrease the risk of glioblastoma-associated brain edema in both mice and patients (162, 163), offering promise for the combination of anti-VEGF therapy and ICIs in the treatment of glioblastoma and possibly brain metastases.”
BackgroundLactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
Kelderman, S., Heemskerk, B., van Tinteren, H., van den Brom, R. R. H., Hospers, G. A. P., van den Eertwegh, A. J. M., Kapiteijn, E. W., de Groot, J. W. B., Soetekouw, P., Jansen, R. L., et al. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1528-9 · Cited by 298
Dirkx, A. E. M., Egbrink, M. G. A. O., Castermans, K., van der Schaft, D. W. J., Thijssen, V. L. J. L., Dings, R. P. M., Kwee, L., Mayo, K. H., Wagstaff, J., Steege, J. C. A. B., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-4493com · Cited by 270
Tran, H. T., Liu, Y., Zurita, A. J., Lin, Y., Baker-Neblett, K. L., Martin, A.-M., Figlin, R. A., Hutson, T. E., Sternberg, C. N., Amado, R. G., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70241-3 · Cited by 261
Choueiri, T. K., Larkin, J., Oya, M., Thistlethwaite, F., Martignoni, M., Nathan, P., Powles, T., McDermott, D., Robbins, P. B., Chism, D. D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30107-4 · Cited by 260
Simeone, E., Gentilcore, G., Giannarelli, D., Grimaldi, A. M., Caracò, C., Curvietto, M., Esposito, A., Paone, M., Palla, M., Cavalcanti, E., et al. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1545-8 · Cited by 253
Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions
Hato, T., Goyal, L., Greten, T. F., Duda, D. G., & Zhu, A. X. (2014) · Hepatology · doi:10.1002/hep.27246 · Cited by 241
Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
Zheng, X., Fang, Z., Liu, X., Deng, S., Zhou, P., Wang, X., Zhang, C., Yin, R., Hu, H., Chen, X., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96582 · Cited by 239 · cited 4×
“IFN-γ elevated the expression of endothelial adhesion molecules ICAM1 and e-selectin, which mediate immunocyte infiltration, decreased that of endothelial VEGFA and increased the expression of CXCL9, CXCL10, and CXCL1, which recruit Th1 cells (41).”
BackgroundInfluentialAmin, A., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Knox, J. J., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5010 · Cited by 233
Rini, B. I., Melichar, B., Ueda, T., Grünwald, V., Fishman, M. N., Arranz, J. A., Bair, A. H., Pithavala, Y. K., Andrews, G. I., Pavlov, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70464-9 · Cited by 231
Huang, Y., Chen, X., Dikov, M. M., Novitskiy, S. V., Mosse, C. A., Yang, L., & Carbone, D. P. (2007) · Blood · doi:10.1182/blood-2007-01-065714 · Cited by 230
Hahn, O. M., Yang, C., Medved, M., Karczmar, G., Kistner, E., Karrison, T., Manchen, E., Mitchell, M., Ratain, M. J., & Stadler, W. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5655 · Cited by 230
Tripathi, C., Tewari, B. N., Kanchan, R. K., Baghel, K. S., Nautiyal, N., Shrivastava, R., Kaur, H., Bhatt, M. L. B., & Bhadauria, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2110 · Cited by 224
Buder-Bakhaya, K., & Hassel, J. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01474 · Cited by 217
The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy
van Beijnum, J. R., Nowak-Sliwinska, P., Huijbers, E. J. M., Thijssen, V. L., & Griffioen, A. W. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010215 · Cited by 211
Roland, C. L., Lynn, K. D., Toombs, J. E., Dineen, S. P., Udugamasooriya, D. G., & Brekken, R. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007669 · Cited by 207
Cheng, A.-L., Qin, S., Ikeda, M., Galle, P., Ducreux, M., Zhu, A., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz446.002 · Cited by 194
Hegde, P. S., Jubb, A. M., Chen, D., Li, N. F., Meng, Y. G., Bernaards, C., Elliott, R., Scherer, S. J., & Chen, D. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2535 · Cited by 193 · cited 1×
“VEGFA121, a secreted isoform of the VEGF-A family (VEGF-A121, VEGF-A165, VEGF-A189, and VEGF-A206) (120), has been intensively studied as a measurable biomarker predicting the efficacy of VEGF targeted agents (121).”
BackgroundFricke, I., Mirza, N., Dupont, J., Lockhart, C., Jackson, A., Lee, J.-H., Sosman, J. A., & Gabrilovich, D. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0409 · Cited by 182
Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
Rini, B. I., Schiller, J. H., Fruehauf, J. P., Cohen, E. E. W., Tarazi, J. C., Rosbrook, B., Bair, A. H., Ricart, A. D., Olszanski, A. J., Letrent, K. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2806 · Cited by 181
Amin, A., Plimack, E. R., Ernstoff, M. S., Lewis, L. D., Bauer, T. M., McDermott, D. F., Carducci, M., Kollmannsberger, C., Rini, B. I., Heng, D. Y. C., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0420-0 · Cited by 180
Sheng, X., Yan, X., Chi, Z., Si, L., Cui, C., Tang, B., Li, S., Mao, L., Lian, B., Wang, X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00210 · Cited by 175
Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
Georganaki, M., van Hooren, L., & Dimberg, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03081 · Cited by 172
Barlesi, F., Scherpereel, A., Gorbunova, V., Gervais, R., Vikström, A., Chouaid, C., Chella, A., Kim, J. H., Ahn, M. J., Reck, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu098 · Cited by 165
Mechanisms of resistance to anti-angiogenesis therapies
Giuliano, S., & Pagès, G. (2013) · Biochimie · doi:10.1016/j.biochi.2013.03.002 · Cited by 158
Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
Rivera, L. B., Meyronet, D., Hervieu, V., Frederick, M. J., Bergsland, E. K., & Bergers, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.055 · Cited by 151
Pancreatic adenocarcinomas with mature blood vessels have better overall survival
Katsuta, E., Qi, Q., Peng, X., Hochwald, S. N., Yan, L., & Takabe, K. (2019) · Scientific Reports · doi:10.1038/s41598-018-37909-5 · Cited by 144
The dark side of tumor-associated endothelial cells
Sanctis, F. D., Ugel, S., Facciponte, J. G., & Facciabene, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.002 · Cited by 143
Macedo, L. T., Lima, A. B. C., & Sasse, A. D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-89 · Cited by 140
Meyerhardt, J. A., Li, L., Sanoff, H. K., Carpenter, W. R., & Schrag, D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9650 · Cited by 139
Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response
Mardis, E. R. (2019) · Genome Medicine · doi:10.1186/s13073-019-0684-0 · Cited by 135
The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic
Ye, W. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.03.015 · Cited by 129
Joshi, S., & Durden, D. L. (2019) · Journal of Oncology · doi:10.1155/2019/5245034 · Cited by 129
Recent advances in the clinical development of immune checkpoint blockade therapy
Ghahremanloo, A., Soltani, A., Modaresi, S. M. S., & Hashemy, S. I. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00456-w · Cited by 127
Integration of pro- and anti-angiogenic signals by endothelial cells
Kazerounian, S., & Lawler, J. (2017) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0433-3 · Cited by 123
Stein, S., Pishvaian, M. J., Lee, M. S., Lee, K.-H., Hernandez, S., Kwan, A., Liu, B., Grossman, W., Iizuka, K., & Ryoo, B. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4074 · Cited by 111
Egfl7 Promotes Tumor Escape from Immunity by Repressing Endothelial Cell Activation
Delfortrie, S., Pinte, S., Mattot, V., Samson, C., Villain, G., Caëtano, B., Lauridant, G., Baranzelli, M., Bonneterre, J. M., Trottein, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1301 · Cited by 110
Gehad, A. E., Lichtman, M. K., Schmults, C. D., Teague, J. E., Calarese, A. W., Jiang, Y., Watanabe, R., & Clark, R. A. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.190 · Cited by 103
Missiaen, R., Mazzone, M., & Bergers, G. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.002 · Cited by 102
Shibaki, R., Murakami, S., Matsumoto, Y., Yoshida, T., Goto, Y., Kanda, S., Horinouchi, H., Fujiwara, Y., Yamamoto, N., Kusumoto, M., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02431-8 · Cited by 101
Budczies, J., Bockmayr, M. L., Denkert, C., Klauschen, F., Gröschel, S., Darb‐Esfahani, S., Pfarr, N., Leichsenring, J., Onozato, M. L., Lennerz, J. K., et al. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22365 · Cited by 99
Wu, X., Giobbie‐Hurder, A., Liao, X., Lawrence, D. P., McDermott, D. F., Zhou, J. M., Rodig, S. J., & Hodi, F. S. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0084 · Cited by 94
Differential roles of angiogenic chemokines in endothelial progenitor cell-induced angiogenesis
Kanzler, I., Tuchscheerer, N., Steffens, G. C. M., Simsekyilmaz, S., Konschalla, S., Kroh, A., Simons, D., Asare, Y., Schober, A., Bucala, R., et al. (2012) · Basic Research in Cardiology · doi:10.1007/s00395-012-0310-4 · Cited by 92
Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine
Lupo, G., Caporarello, N., Olivieri, M., Cristaldi, M., Motta, C., Bramanti, V., Avola, R., Salmeri, M., Nicoletti, F., & Anfuso, C. D. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00519 · Cited by 90
Characterization and Regulation of Bv8 in Human Blood Cells
Zhong, C., Qu, X., Tan, M., Meng, Y. G., & Ferrara, N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1954 · Cited by 89
Faruque, L. I., Lin, M., Battistella, M., Wiebe, N., Reiman, T., Hemmelgarn, B. R., Thomas, C. M., & Tonelli, M. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101145 · Cited by 87
Ipilimumab and Bevacizumab in Glioblastoma
Carter, T. J., Shaw, H. M., Cohn-Brown, D., Chester, K. A., & Mulholland, P. J. (2016) · Clinical Oncology · doi:10.1016/j.clon.2016.04.042 · Cited by 85
Gadgeel, S. M., Stevenson, J. P., Langer, C. J., Gandhi, L., Borghaei, H., Patnaik, A., Villaruz, L. C., Gubens, M. A., Hauke, R. J., Yang, J. C., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.08.019 · Cited by 85
Liu, X., Qin, S., Wang, Z., Xu, J., Xiong, J., Bai, Y., Wang, Z., Yang, Y. F., Sun, G., Wang, L., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0521-0 · Cited by 82
Long, J., Hu, Z., Xue, H., Wang, Y., Chen, J., Tang, F., Zhou, J., Liu, L., Qiu, W., Zhang, S., et al. (2019) · Cancer Science · doi:10.1111/cas.14091 · Cited by 82
Jreige, M., Letovanec, I., Chaba, K., Renaud, S., Rusakiewicz, S., Cristina, V., Peters, S., Krueger, T., de Leval, L., Kandalaft, L. E., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04348-x · Cited by 81
CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils
Zheng, X., Zhang, N., Qian, L., Wang, X., Fan, P., Kuai, J., Lin, S., Liu, C., Jiang, W., Qin, S., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32829 · Cited by 81
Balatoni, T., Mohos, A., Papp, E., Sebestyén, T., Liszkay, G., Oláh, J., Varga, A., Lengyel, Z., Emri, G., Gaudi, I., et al. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2072-1 · Cited by 76
Laskin, J. J., Crinò, L., Felip, E., Franke, F. A., Горбунова, В. А., Groen, H. J. M., Jiang, G.-L., Reck, M., & Schneider, C.-P. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182370e02 · Cited by 72
Petrelli, F., Borgonovo, K., Cabiddu, M., Ghilardi, M., Lonati, V., Maspero, F., Sauta, M. G., Beretta, G. D., & Barni, S. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.04.006 · Cited by 69
Fukuoka, S., Hara, H., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2522 · Cited by 69
Galetta, D., Cinieri, S., Pisconti, S., Gebbia, V., Morabito, A., Borsellino, N., Maiello, E., Febbraro, A., Catino, A., Rizzo, P., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.002 · Cited by 68
Zhu, A. X., Finn, R. S., Ikeda, M., Sung, M. W., Baron, A. D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4519 · Cited by 68
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma
Gao, X. Y., & McDermott, D. F. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1513485 · Cited by 67
Plimack, E. R., Rini, B. I., Stus, V. P., Gafanov, R. A., Waddell, T., Nosov, D., Pouliot, F., Soulières, D., Melichar, B., Vynnychenko, I. O., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.5001 · Cited by 65
Qin, L., Li, X., Stroiney, A., Qu, J., Helgager, J., Reardon, D. A., & Young, G. S. (2017) · Neuroradiology · doi:10.1007/s00234-016-1769-8 · Cited by 64
Mulligan, J. K., Day, T. A., Gillespie, M. B., Rosenzweig, S. A., & Young, M. R. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.01.014 · Cited by 58
Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report
Zhu, X., McDowell, M. M., Newman, W. C., Mason, G. E., Greene, S., & Tamber, M. S. (2017) · Journal of Neurosurgery: Pediatrics · doi:10.3171/2016.8.peds16326 · Cited by 53
Langer, C. J., Socinski, M. A., Patel, J. D., Sandler, A. B., Schiller, J. H., Leon, L., Hazard, S. J., & Ramalingam, S. S. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000163 · Cited by 50
Control of the Adaptive Immune Response by Tumor Vasculature
Mauge, L., Terme, M., Tartour, É., & Helley, D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00061 · Cited by 49
Szukiewicz, D., Kochanowski, J., Pyźlak, M., Szewczyk, G., Stangret, A., & Mittal, T. K. (2013) · Mediators of Inflammation · doi:10.1155/2013/437576 · Cited by 47
Poddubskaya, E. V., Baranova, M. P., Allina, D. O., Smirnov, P. Y., Albert, E. A., Kirilchev, A., Aleshin, A. A., Sekacheva, M. I., & Suntsova, M. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0113-x · Cited by 45
Uemura, M., Tomita, Y., Miyake, H., Hatakeyama, S., Kanayama, H., Numakura, K., Takagi, T., Kato, T., Eto, M., Obara, W., et al. (2019) · Cancer Science · doi:10.1111/cas.14294 · Cited by 44
Malo, C. S., Khadka, R. H., Ayasoufi, K., Jin, F., Chehade, J. E. A., Hansen, M. J., Iezzi, R., Pavelko, K. D., & Johnson, A. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00320 · Cited by 43
Zhuang, J., Du, J., Guo, X., Zhou, J., Duan, L., Qiu, W., Si, X., Zhang, L., Li, Y., Liu, X., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13281 · Cited by 43
Jonasch, E. W., Slack, R. S., Geynisman, D. M., Hasanov, E., Milowsky, M. I., Rathmell, W. K., Stovall, S., Juarez, D., Gilchrist, T. R., Pruitt, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.1485 · Cited by 41
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
Wakabayashi, G., Lee, Y., Luh, F., Kuo, C.-N., Chang, W., & Yen, Y. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0588-8 · Cited by 40
Rizvi, N. A., Antonia, S. J., Shepherd, F. A., Chow, L. Q. M., Goldman, J. W., Shen, Y., Chen, A. C., & Gettinger, S. N. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.08.206 · Cited by 37
Perdrizet, K., & Leighl, N. B. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0617-6 · Cited by 36
The Raf Kinase Inhibitor Sorafenib Inhibits JAK–STAT Signal Transduction in Human Immune Cells
del Campo, S. E. M., Levine, K. M., Mundy-Bosse, B. L., Grignol, V. P., Fairchild, E. T., Campbell, A. R., Trikha, P., Mace, T. A., Paul, B. K., Jaime‐Ramirez, A. C., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1400084 · Cited by 32
Sun, L., Ma, J., Zhang, S., Zou, H., & Han, C. (2015) · Medical Oncology · doi:10.1007/s12032-014-0473-y · Cited by 31
Immunotherapy-based combinations: an update
Fucà, G., de Braud, F., & Nicola, M. D. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000466 · Cited by 27
Chau, I., Bendell, J. C., Calvo, E., Santana-Dávila, R., Rodon, J. A., Penel, N., Arkenau, H., Yang, J., Rege, J. M., Mi, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.102 · Cited by 26
Galati, D., Zanotta, S., Canora, A., Polistina, G. E., Nicoletta, C., Ghinassi, G., Ciasullo, E., & Bocchino, M. (2019) · Cytokine · doi:10.1016/j.cyto.2019.154831 · Cited by 24
Markovic, S. N., Suman, V. J., Javed, A., Reid, J. M., Wall, D. J., Erickson, L. A., Ernstoff, M. S., & Anderson, D. M. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000644 · Cited by 24
Anti-angiogenesis in Personalized Therapy of Lung Cancer
Ellis, P. M. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24223-1_5 · Cited by 22
Gou, M., Yan, H., Liu Tie, E., Wang, Z., Si, H., Chen, S., Pan, Y., Fan, R., Qian, N., & Dai, G. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4028 · Cited by 20
Hurwitz, H. I., & Lyman, G. H. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7031 · Cited by 16
Khakoo, S. S., Chau, I., Pedley, I. D., Ellis, R. E., Steward, W. P., Harrison, M., Baijal, S., Tahir, S., Ross, P. J., Raouf, S., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.07.003 · Cited by 16
Han, B., Chu, T., Zhong, R., Zhong, H., Zhang, B., Zhang, W., Shi, C., Qian, J., & Han, Y. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.269 · Cited by 15
Self-citationHerbst, R. S., Martín-Liberal, J., Calvo, E., Isambert, N., Bendell, J. C., Cassier, P. A., Jin, J., Mi, G., Rege, J. M., & Paz-Ares, L. G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx091.010 · Cited by 13
Rebuzzi, S. E., Facchinetti, F., & Tiseo, M. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.06.21 · Cited by 12
Sheng, X., Yan, X., Chi, Z., Si, L., Cui, C., Tang, B., Li, S., Mao, L., Lian, B., Wang, X., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.10007 · Cited by 12
Liu, X., Qin, S., Wang, Z., Xu, J., Xiong, J., Bai, Y., Wang, Z., Yan, Y., Sun, G., Wang, L., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0545-5 · Cited by 11
Immunotherapy-based combinations: current status and perspectives
Miguel, M. J. D., Mansinho, A., Boni, V., & Calvo, E. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000391 · Cited by 10
Vogel, A., Rimassa, L., Sun, H., Abou‐Alfa, G. K., El-Khoueiry, A. B., Pinato, D. J., Daigl, M., Alvarez, J. S., Orfanos, P., Leibfried, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4585 · Cited by 8
Vrecko, S., Guenat, D., Mercier‐Letondal, P., Faucheu, H., Dosset, M., Royer, B., Galaine, J., Boidot, R., Kim, S. C. H., Jary, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26247 · Cited by 7
Wu, C.-J., Hung, Y., Lee, P. C., Lee, C.-J., Chen, M., Chao, Y., Hou, M., & Huang, Y. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.e16627 · Cited by 6
Widick, P. C., Gill, R. R., Mantia, C. M., Costa, D. B., & Rangachari, D. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.09.005 · Cited by 4
Cited by
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Cancer associated-fibroblast-derived exosomes in cancer progression
Li, C., Teixeira, A. F., Zhu, H.-J., & ten Dijke, P. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01463-y · Cited by 336
Zhang, W., Jin, C., Liu, S., Wan, X., Li, Y., Liu, J., Duan, Z., Ma, J., & Gao, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1757513 · Cited by 22
Metadata
- Authors
- Song, Y., Fu, Y., Xie, Q., Zhu, B., Wang, J., & Zhang, B.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-08-25
- Volume
- 11
- Pages
- 1956-1956
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3080850044
- Cited by
- 261
- References
- 155
- FWCI
- 12.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.